| Hans-Günter Meyer-Thompson | Legal
UNAIDS urges Gilead to drop price of new HIV prevention shot
UNAIDS urges Gilead to drop price of new HIV prevention shot
GENEVA, 18 June 2025—The United States Food and Drug Administration (FDA) has approved long-acting injectable lenacapavir for HIV prevention. The new medicine is administered by injection once every 6 months and is a significant step in improving prevention options for people at risk of HIV infection around the world. In an interview with the New York Times, Gilead Sciences has announced a US list price of $28,218 USD per person per year. (UNAIDS, Genf, 18.06.2025)